Results for "consumer data right"
261-270 of 667 results for 'consumer data right'
PBS process proving a headache for migraine medications
Challenging a PBAC decision is not straightforward. We take a look at the available options and examine the alleged delays in listing migraine treatments Emgality and Ajovy on the PBS. ...
Privacy disclosure incident leads to largest ever award of compensation for non-economic loss.
The determination issued by the OAIC for breaches of the Privacy Act by the Department of Home Affairs confirms that compensation can be ordered to be paid for non-economic losses related to data breaches. ...
Repurposing existing medicines – industry to have its say in reshaping Australia's regulatory future
The Therapeutics Goods Administration (the TGA) is consulting with the public and industry to potentially reform regulatory and reimbursement frameworks, to incentivise the repurposing of existing medicines. Off-label use (where a medicine is used for a disease or medical condition for which it does ...
How to determine whether you have suffered an eligible data breach
From 22 February 2018 the Notifiable Data Breaches Scheme NDB Scheme will require all entities covered by the regime to notify the Office of the Australian Information Commissioner OAIC and affected individuals of an eligible data breach ...
Directors' duties and cyber resilience
The Target data breach brought the liability of boards and directors in relation to cyber resilience into focus. Target's shareholders brought litigation against all of its directors, the chief financial officer and the chief information officer due to what was perceived as recklessness and disregar ...
TGA guidance on the promotion of medicinal cannabis
The Therapeutic Goods Administration (TGA) has issued guidance on advertising to the public for businesses involved with medicinal cannabis products and therapies. Along with advertising restrictions, ...
TGA guidance on the promotion of stem cells and HCT products
The Therapeutic Goods Administration has issued advertising guidance for businesses involved with stems cells and other human cell or tissue products. ...
Takeaways from recent guidance on cyber incident disclosure obligations for listed companies
In this Insight, we examine the guidance note and related developments and offer our view as to when disclosure (for the purposes of the ASX listing rule requirements) of cyber incidents should generally only occur. ...
Ever-expanding jurisdiction: Clearview AI's appeal and extra-territorial application of the Privacy Act
A landmark ruling in Australia confirms that Clearview AI breached the Privacy Act despite lacking a physical presence or supplying products or services in the country, emphasising the extraterritorial reach of privacy laws and the consequences for companies. ...
Imitation is not always the sincerest form of flattery
In this issue we examine a patentees ability to enforce Swiss-style claims against makers of bioequivalent products following the Mylan Health decision ...